You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Phase I clinical study evaluates DCP-001, the company’s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment. The ALISON study is carried out by Professor Hans Nijman and his research group in Groningen, theAlready a subscriber Login You have read…
The company has reported positive results from the ongoing CANFOUR trial investigating nadunolimab (CAN04) in combination with gemcitabine/nab-paclitaxel (Abraxane) for first line treatment of patients with advanced pancreatic cancer (PDAC). The efficacy analysis included 33 patients. Overall, thAlready a subscriber Login You have read all your free articles, to continue…
Pharmalink has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon. Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess Already a subscriber Login You have read all your…
AlzeCure Pharma has received a response from the US Food and Drug Administration (FDA) regarding the preIND application that was submitted prior to the planned phase IIa study with ACD440 in neuropathic pain. ACD440 completed a positive phase Ib study in 2021 and the company now plans to initiateAlready a…
